Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders (2002)
Chapter: Appendix C: Chronology of Important Events Regarding Vaccine Safety
Appendix C
Chronology of Important Events Regarding Vaccine Safety
Year | Vaccine Licensure | Legislation and/or Policy Statements | IOM Reports on Vaccine Safety |
1955 | Inactivated poliomyelitis vaccine (IPV) available |
| |
1963 | Oral poliomyelitis vaccine (OPV) available, replaces IPV | ||
| Measles vaccine available | ||
1967 | Mumps vaccine available | ||
1969 | Rubella vaccine available | ||
1971 | Measles-Mumps-Rubella (MMR) vaccine available | ||
1977 |
| Mumps vaccination recommended | Evaluation of Poliomyelitis Vaccines |
1979 | Current formulation of rubella vaccine available, replaces earlier versions |
| |
1982 | Plasma-derived hepatitis B vaccine available | ||
Year | Vaccine Licensure | Legislation and/or Policy Statements | IOM Reports on Vaccine Safety |
1985 | Hib vaccine licensed for children>15 months |
| |
1986 |
| Congress passes Public Law 99–660, the National Childhood Vaccine Injury Act (introduced in 1984) calls for: • est of NVPO • est. of NVAC • est. of VICP • est. of ACCV IOM review of 1) pertussis and rubella, 2) routine child vaccines |
|
1988 |
| Evaluation of Poliomyelitis Vaccine Policy Options | |
1990 | 2 Hib conjugate vaccines licensed for use beginning at 2 months |
| |
1991 | Acellular pertussis component licensed for the 4th and 5th doses of the 5-part DTP series in ACEL-IMUNE | Hepatitis B recommended by ACIP for addition to childhood immunization schedule | Adverse Effects of Pertussis and Rubella Vaccines |
ACIP recommends Hib be added to childhood immunization schedule | |||
1992 | Acellular pertussis component licensed for the 4th and 5th doses of the 5-part DTP series in Tripedia | Hepatitis B vaccine: Added universal vaccination for all infants, high-risk adolescents (e.g., IV drug users, persons with multiple sex partners) |
|
1993 | Combined DTP and Hib vaccine (Tetramune) licensed |
| |
1994 |
| Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality | |
DPT and Chronic Nervous System Dysfunction: A New Analysis | |||
1995 | Varicella virus vaccine available (Varivax) |
| |
Year | Vaccine Licensure | Legislation and/or Policy Statements | IOM Reports on Vaccine Safety |
1996 | DTaP vaccine licensed for first three doses given in infancy (Tripedia and ACEL-IMUNE were previously licensed for only the 4th and 5th doses). | ACIP recommends using IPV for the first 2 polio vaccinations, followed by OPV for remaining doses. Intended to be a transitional schedule for 3–5 years until an all-IPV series is available | Options for Poliomyelitis Vaccinations in the United States: Workshop Summary |
| ACIP recommends children 12months–12 years receive Varicella vaccine |
| |
1997 | Additional DTaP vaccine (Infanrix) licensed for first 4 doses of 5-part series | ACIP recommends DTaP in place of DTP | Vaccine Safety Forum: Summary of Two Workshops |
| Risk Communication and Vaccination: Workshop Summary | ||
1998 | Additional DTaP vaccine (Certiva) licensed for first 4 doses of 5-part series | ACIP updates MMR recommendation, encouraging use of the combined MMR vaccine |
|
1999 |
| ACIP updates varicella vaccine recommendation, requiring immunity for child care and school entry | |
ACIP recommends an all-IPV schedule begin January 2000 to prevent cases of vaccine-associated paralytic polio | |||
AAP and PHS recommend removal of thimerosal from vaccines Also recommended postponement of hepatitis B vaccine from birth to 2–6 months for infants of hepatitis B surface antigen-negative mothers | |||
Additional supply of thimerosal-free hepatitis B vaccine made available | MMWR notifies readers of the availability of a thimerosal-free hepatitis B vaccine, enabling the resumption of the birth dose |
| |
2000 | Pneumococcal vaccine for infants and young | ACIP recommends pneumococcal vaccination for all chil |
|
Year | Vaccine Licensure | Legislation and/or Policy Statements | IOM Reports on Vaccine Safety |
| children licensed (Prevnar) | dren 2–23 months, and at-risk children 24–59 months (e.g., immunocompromised) |
|
2001 |
| October: ACIP drafts statement expressing a preference for use of thimerosal-free DtaP, Hib, and Hep B vaccines by March 2002 | Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism |
| Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders | ||
2002 |
| Immunization Safety Review: Multiple Immunizations and Immune Dysfunction | |
